bortezomib + gemcitabine + pegylated liposomal doxorubicin

This combination therapy consists of the proteasome inhibitor bortezomib, the nucleoside analog gemcitabine, and pegylated liposomal doxorubicin (Doxil). It was investigated by the M.D. Anderson Cancer Center in a Phase I dose-escalation study for the treatment of advanced solid tumors and lymphomas. Bortezomib works by reversibly inhibiting the 26S proteasome, leading to the disruption of protein homeostasis and induction of apoptosis. Gemcitabine is a pro-drug that, once phosphorylated, inhibits DNA synthesis by inhibiting ribonucleotide reductase and competing with dCTP for incorporation into DNA. Pegylated liposomal doxorubicin is a nanoparticle formulation of the anthracycline doxorubicin, which intercalates into DNA and inhibits topoisomerase II, causing double-strand DNA breaks. The liposomal delivery system is designed to enhance tumor accumulation and reduce the cardiotoxicity typically associated with conventional doxorubicin.

Other names

Doxil + Velcade + Gemcitabinepegylated liposomal doxorubicin + bortezomib + gemcitabinebortezomib + gemcitabine + liposomal doxorubicin